Livanova

OverviewSuggest Edit

LivaNova is a global medical technology company. The company provides cardiac surgery, neuromodulation, and cardiac rhythm management solutions.

TypePublic
Founded2015
HQLondon, GBMap
Websitelivanova.com
Employee Ratings3.5More
View Jobs (67)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)4,000
Job Openings67
Revenue (FY, 2019)$1.1 B(-2%)
Share Price (May 2020)$52.7 (+4%)

Key People/Management at Livanova

Damien McDonald

Damien McDonald

Chief Executive Officer and Director
Thad Huston

Thad Huston

Chief Financial Officer
Francesco Bianchi

Francesco Bianchi

Director
Keyna Skeffington

Keyna Skeffington

Senior Vice President, General Counsel
William Kozy

William Kozy

Director
Hugh Morrison

Hugh Morrison

Director
Show more

Livanova Office Locations

Livanova has offices in London, Brockworth, Houston, Dandenong South and in 14 other locations
London, GB (HQ)
20 Eastbourne Terrace
Brockworth, GB
1370, Montpellier Court, Gloucester Business Park
Dandenong South, AU
16-18 Hydrive Cl
Wien, AT
Schottengasse 1
Markham, CA
280 Hillmount Rd #8
Bogotá, CO
Cra. 33 ##15-39
Show all (19)

Livanova Financials and Metrics

Livanova Revenue

Livanova's revenue was reported to be $1.08 b in FY, 2019
USD

Revenue (Q1, 2020)

242.4m

Gross profit (Q1, 2020)

173.5m

Gross profit margin (Q1, 2020), %

71.6%

Net income (Q1, 2020)

37.6m

EBIT (Q1, 2020)

608.0k

Market capitalization (26-May-2020)

2.6b

Closing stock price (26-May-2020)

52.7

Cash (31-Mar-2020)

125.8m

EV

3.0b
Livanova's current market capitalization is $2.6 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

415.7m1.2b1.0b1.1b1.1b

Cost of goods sold

149.2m472.0m353.4m361.8m

Gross profit

266.5m741.9m658.9m745.1m

Gross profit Margin, %

64%61%65%67%
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

287.0m321.0m295.3m285.1m321.4m309.7m250.4m287.5m272.1m250.8m277.2m268.6m242.4m

Cost of goods sold

123.6m130.7m106.5m101.5m108.9m108.2m84.6m92.0m94.3m84.3m74.9m86.1m68.9m

Gross profit

163.4m190.4m188.8m183.6m212.5m201.4m165.8m195.5m177.8m166.5m202.2m182.5m173.5m

Gross profit Margin, %

57%59%64%64%66%65%66%68%65%66%73%68%72%
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(29.6m)(62.8m)(25.1m)(189.4m)(155.2m)

Depreciation and Amortization

20.5m45.5m37.1m69.9m70.7m

Inventories

36.3m26.7m7.2m(10.6m)(10.6m)

Cash From Operating Activities

(9.3m)90.2m91.3m120.5m(91.1m)
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

1.0k(40.4m)(31.4m)(33.0m)11.3m58.8m86.6m13.3m28.3m21.2m(14.8m)(44.1m)(11.9m)37.6m

Depreciation and Amortization

23.6m41.7m34.0m20.2m41.1m63.3m17.1m35.2m53.0m16.9m33.8m52.8m17.1m

Inventories

10.8m24.7m20.6m(4.4m)(6.9m)(11.0m)(6.3m)(11.3m)(7.6m)(8.3m)(14.3m)(18.2m)(12.5m)

Cash From Operating Activities

9.6m12.6m49.3m33.2m31.6m73.7m20.4m48.5m99.6m2.0m(17.4m)(94.0m)(106.0m)
show all
USDY, 2020

EV/EBIT

5 k x

EV/CFO

-28.4 x

Financial Leverage

1.8 x
Show all financial metrics

Livanova Online and Social Media Presence

Livanova's Trends

Embed Graph

Livanova News and Updates

January 17, 2020

Focus on Sleep Apnea Implant Market Changing the Way of Business in Upcoming Year with Profiling Key Nyxoah, LivaNova, Invacare

The global Sleep Apnea Implant market is valued at XX million USD in 2020 and is expected to reach XX million USD by the end of 2026, growing at a CAGR of XX% between 2020 and 2026. Posted via Industry Today. Follow us on Twitter @IndustryToday
November 20, 2019

LivaNova to restructure heart valve unit

Medical device maker LivaNova Plc said on Wednesday it will restructure its heart valve business that could impact about 150 employees in three of its facilities.
May 02, 2019

Global Heart Valve Repair and Replacement Devices Market to 2023 - Key Vendors are Abbott, Boston Scientific, CryoLife, Edwards Lifesciences, LivaNova, & Medtronic

DUBLIN, May 2, 2019 /PRNewswire/ -- The "Global Heart Valve Repair and Replacement Devices Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. The analysts have predicted that the heart valve repair and replacement devices market will register a CAGR of nearly...
January 16, 2019

Neuromodulation Market 2023 report provides Latest improvements in the industry by anticipating the future perspective of the market, competitors, the top key players such as Medtronic plc, St. Jude Medical, Inc., LivaNova PLC

The Global Neuromodulation Market is an analysis and portrayal of the market globally. It gives a clear image of the market and a thoughtful knowledge about its segments. The various sections are examined and is the key part of the Neuromodulation Market. Posted via Industry Today. Follow us on Twit…
January 15, 2019

Cardiopulmonary Bypass Equipment Market Expected to Witness the Highest Growth 2026 | With Global Key Players Medtronic Plc, LivaNova PLC, MAQUET Holding B.V. & Co. KG., Terumo Corporation, Braile Biomedica, Tianjin Medical

Cardiopulmonary bypass equipment is a machine which takes over the function of heart and lungs to maintain the circulation of blood and the oxygen content of the patient's body during coronary bypass heart surgery. Posted via Industry Today. Follow us on Twitter @IndustryToday
December 07, 2018

Global Cardiac Prosthetic Devices Market Attractiveness, Competitive Landscape and Key Players Boston scientific, Medtronic, Livanova, Edward lifesciences, ST.jude medical, Elkem Silicones, Integer Holdings Corporation, Getinge AB

Market research Report on Cardiac Prosthetic Devices industry providing global and Chinese Market Landscape and its Growth Prospects over the approaching years until 2025 is currently offered at The Insight Partners Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

Livanova Blogs

March 30, 2020

LivaNova to Host Conference Call for First Quarter 2020 Results

LONDON --(BUSINESS WIRE)--Mar. 30, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2020 results on Wednesday, April 29, 2020 at 1 p.m. London time ( 8 a.m. Eastern Daylight Time ).
March 26, 2020

LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at American College of Cardiology and World Congress of Cardiology Virtual Meeting

LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at American College of Cardiology and World Congress of Cardiology Virtual Meeting Content Import Thu, 03/26/2020 - 09:00 LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at Ame…
March 09, 2020

LivaNova VNS Therapy System, Symmetry, Granted CE Mark for Difficult-to-Treat Depression

Two UK patients receive innovative VNS Therapy implantable device through new pathway LONDON --(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Vagus Nerve Stimulation Therapy ® (VNS Therapy) System, Symmetry™, earned CE
February 26, 2020

LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depression

LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depression Katherine.Howe… Wed, 02/26/2020 - 16:44 LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact o…
February 26, 2020

LivaNova Reports Fourth Quarter and Full-Year 2019 Results

LONDON --(BUSINESS WIRE)--Feb. 26, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2019 . For the fourth quarter of 2019, worldwide sales were $287.6 million , a decrease of 3.2
February 25, 2020

LivaNova Receives FDA Clearance for 3T Heater-Cooler Device Modification

LONDON --(BUSINESS WIRE)--Feb. 25, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for a device modification to its 3T Heater-Cooler ® devices.
Show more

 Livanova Frequently Asked Questions

  • When was Livanova founded?

    Livanova was founded in 2015.

  • Who are Livanova key executives?

    Livanova's key executives are Damien McDonald, Thad Huston and Francesco Bianchi.

  • How many employees does Livanova have?

    Livanova has 4,000 employees.

  • What is Livanova revenue?

    Latest Livanova annual revenue is $1.1 b.

  • What is Livanova revenue per employee?

    Latest Livanova revenue per employee is $271 k.

  • Who are Livanova competitors?

    Competitors of Livanova include Edwards Lifesciences, Sonacare Medical and Vascular Graft Solutions.

  • Where is Livanova headquarters?

    Livanova headquarters is located at 20 Eastbourne Terrace, London.

  • Where are Livanova offices?

    Livanova has offices in London, Brockworth, Houston, Dandenong South and in 14 other locations.

  • How many offices does Livanova have?

    Livanova has 19 offices.